Naxifylline is an A1 Adenosine Receptor Antagonist used for the Treatment of Edema Associated with Congestive Heart Failure. Naxifylline protects against the decline in renal function observed with diuretic therapy by promoting urine output. References: Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002 Mar 19;105(11):1348-53. Erratum in: Circulation 2002 Sep 24;106(13):1743. PubMed PMID: 11901047. 2: Gottlieb SS, Skettino SL, Wolff A, Beckman E, Fisher ML, Freudenberger R, Gladwell T, Marshall J, Cines M, Bennett D, Liittschwager EB. Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol. 2000 Jan;35(1):56-9. PubMed PMID: 10636259.

纯度：≥98%

CAS：166374-49-8